<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To investigate the activity of a novel <z:chebi fb="0" ids="39430">dioxolane</z:chebi> L-<z:chebi fb="0" ids="33838">nucleoside</z:chebi> analog, troxacitabine (L-(-)-OddC, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCH</z:e>-4556), in patients with refractory <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Study participants were patients with refractory or relapsed <z:hpo ids='HP_0011009'>acute</z:hpo> myeloid (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) or lymphocytic (ALL) <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), or <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> in <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blastic phase</z:e> (<z:mp ids='MP_0005481'>CML</z:mp>-BP) </plain></SENT>
<SENT sid="2" pm="."><plain>Troxacitabine was provided as an intravenous infusion for more than 30 minutes daily for 5 days at a dose of 8.0 mg/m(2)/d (40 mg/m(2) per course) </plain></SENT>
<SENT sid="3" pm="."><plain>Courses were given every 3 to 4 weeks according to antileukemic efficacy </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Forty-two patients (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 18 patients; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, one patient; ALL, six patients; <z:mp ids='MP_0005481'>CML</z:mp>-BP, 17 patients) were treated </plain></SENT>
<SENT sid="5" pm="."><plain>Median age was 51 years (range, 23 to 80 years); 22 patients were male </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0010280'>Stomatitis</z:hpo> was the most significant adverse event, with three patients (7%) and two patients (5%), respectively, experiencing grade 3 or 4 toxicity </plain></SENT>
<SENT sid="7" pm="."><plain>Ten patients (24%) had grade 3 hand-foot syndrome, and two patients (5%) had grade 3 <z:hpo ids='HP_0000988'>skin rash</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>One patient (2%) had grade 3 <z:mp ids='MP_0002899'>fatigue</z:mp> and <z:hpo ids='HP_0002039'>anorexia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Marrow <z:mpath ids='MPATH_133'>hypoplasia</z:mpath> occurred between days 14 and 28 in 12 (75%) of 16 assessable patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Two complete remissions and one partial remission (18%) were observed in 16 assessable patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>None of six patients with ALL responded </plain></SENT>
<SENT sid="12" pm="."><plain>Six (37%) of 16 assessable patients with <z:mp ids='MP_0005481'>CML</z:mp>-BP experienced a return to <z:hpo ids='HP_0011010'>chronic</z:hpo>-phase disease </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSION: Troxacitabine has significant antileukemic activity in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:mp ids='MP_0005481'>CML</z:mp>-BP </plain></SENT>
</text></document>